Alternatives to Potere Health MD

$99/mo semaglutide, $183/mo tirzepatide, all 50 states, a named physician personally reviewing every intake, and a real 5-7 day timeline — on a broader peptide platform where GLP-1 pricing is genuinely invisible unless you know to pull the page's own data bundle.

A flat $88/mo semaglutide and $157/mo tirzepatide with named medical groups and pharmacies behind it — the cheapest sticker in this batch, but a video visit is required and cancellation is by email, not a dashboard toggle.

Compounded semaglutide at $79 a month and tirzepatide at $119, month to month, with no dose-based increase and — checked in its own checkout data rather than taken on trust — a renewal price identical to the joining price. That last part is rarer than it should be. Two things the homepage will not tell you. The $49 and $99 it advertises are the twelve-month totals divided by twelve, not a monthly rate you can start on, and the countdown beside them is not a real deadline: it read August 15th and then August 20th within the same hour. The larger caveat is corporate. NextMeds is operated by Trinity HealthCare Supply, LLC, which also runs Lean Meds, altRx and Trinity Meds, and that operator holds an open FDA warning letter.

For a working mother the appeal here is logistics as much as money: a fully online intake with no video call to schedule, all 50 states, and one flat charge per month that covers the visit, the plan, the medication and shipping — held at the same price whatever dose you end up on. Month to month that is $79 for compounded semaglutide and $109 for compounded tirzepatide; the $69 the homepage headlines under a countdown timer is the twelve-month tier, and $95 is its tirzepatide equivalent. Flat-by-dose is the part that actually protects a budget, because dose-priced providers routinely double between a starting and a maintenance dose. Two things to weigh against that. The off-ramp is narrow: subscriptions auto-renew, canceling means emailing care@leanmeds.com at least 48 hours before the processing date, and the order stops being refundable the moment you submit the medical intake. And the operator named throughout its own Terms — Trinity HealthCare Supply, LLC — is the company FDA wrote to on 8 June 2026 under its other brand, altRx, for labeling compounded vials with its own name when it was not the compounder and for calling compounded GLP-1s 'clinically proven.' That letter concerns altrx.com, not this site, but it is the same legal entity at the same Miami suite, and no pharmacy or clinician is named here either.

Flat at every dose - $99 semaglutide, $134 tirzepatide, all fifty states - which makes the annual math trivial. The site never names its operating company.

An all-inclusive $89/mo semaglutide program, LegitScript-certified and licensed in all 50 states — undercut by a homepage that advertises a different $99 first-month figure for the same product, and a tirzepatide option that's listed but never separately priced.

$99 semaglutide, $149 tirzepatide, flat at every dose, all 50 states. Renewal prices match advertised prices in the checkout data, so the no-price-rise claim holds. A plan month is four weeks; the '12-month' plan at $999 is 48 weeks. Same operator as Lean Meds, altRx and NextMeds — one company, four storefronts — and that operator holds FDA letter 728236, still open.

FDA warning letter #721472 (Feb. 2026), which names newself.com. A flat, dose-independent price for both molecules — $99.97/mo semaglutide, $144.49/mo tirzepatide, same price at every dose — nationwide, though it requires 3 months upfront.

One of the lowest disclosed GLP-1 starting prices in this round — from $99/mo semaglutide, $133/mo tirzepatide — with an explicit no-membership, no-hidden-fee claim, though the real ongoing rate at a working dose isn't confirmed.